Immunome (IMNM) Enterprise Value (2019 - 2026)

Immunome has reported Enterprise Value for 8 years, with the latest figure at -$582.7 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 83.64% year-over-year to -$582.7 million; the trailing twelve-month figure through Mar 2026 stood at -$582.7 million (down 83.64% YoY), and the FY2025 full-year result was -$653.5 million, down 200.72% from the prior year.
• Enterprise Value for Q1 2026 stood at -$582.7 million, up from -$653.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$20.3 million in Q4 2022, with the low at -$653.5 million in Q4 2025.
• Historically, Enterprise Value has averaged -$210.4 million across 5 years, with a median of -$217.3 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 58.72% — and 2024, when it sank 624.58%.
• Immunome's Enterprise Value stood at -$20.3 million in 2022, then tumbled by 579.73% to -$138.1 million in 2023, then tumbled by 57.3% to -$217.3 million in 2024, then plunged by 200.72% to -$653.5 million in 2025, then rose by 10.83% to -$582.7 million in 2026.
• The last three Enterprise Value figures came in at -$582.7 million (Q1 2026), -$653.5 million (Q4 2025), and -$272.6 million (Q3 2025), per Business Quant data.